Stiripentol
- TRADE NAME: Diacomit (Biocodex SA)
- INDICATIONS: treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.
- HALF-LIFE: 4.5–13 hours
FDA APPROVAL DATE: 08/20/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: N/A
Based on animal data, may cause fetal harm
Please login to see the rest of this drug profile
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 02/16/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric